31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The present review integrates findings of published studies that have evaluated the cognitive function of treated and untreated type 2 diabetic patients and provides a detailed overview of the neuropsychological assessments conducted. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Ciliary neurotrophic factor (CNTF) is the most extensively studied member of the cytokine family that signal through intracellular chains of the gp130/LIFRβ receptor. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease,* the most common cause of dementia, affects an estimated 6.5 million persons aged ≥65 years in the United States (1). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Educational attainment and physical activity PRSs were associated with AD in both sexes. 5 key findings →
Design: systematic review Participants: 27,751 Evidence: high
Full summary, score breakdown and related studies → Original source
Frailty index was associated with carboxylic acids and derivatives, fatty acyls and organooxygen compounds across multiple clusters, and a large number of lipids were linked to frailty score, potentially implicating dysregulation of energy metabolism in the pathophysiology of frailty and forming a panel of predictive biomarkers of at risk patients. 3 key findings →
Participants: 118 Evidence: low
Full summary, score breakdown and related studies → Original source
The association declines monotonically as control over ascertainment improves. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dysregulated insulin signaling in brain has been linked to cognitive impairment and dementia. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component. 3 key findings →
Design: meta-analysis Participants: 213,604 Evidence: high
Full summary, score breakdown and related studies → Original source
Four distinct subtypes were identified: I low-risk healthy aging, II behavioral/social vulnerability, III cardiometabolic–depressive multimorbidity, and IV mixed social-medical vulnerability profiles. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Eligible studies reported MACE or dementia outcomes in adults ≥ 50 years for at least one of three intervention classes (RZV, SGLT2i, GLP-1 RA) versus placebo or active comparator, with follow-up ≥ 6 months. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
In this nationwide cohort, probucol use was associated with substantially lower dementia risk than statins, supporting evaluation of probucol for repurposing in dementia prevention. 2 key findings →
Participants: 52,532 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Long-term metformin treatment is associated with a reduced risk of dementia and better memory performance among persons with pre-diabetes or T2D. Longer follow-up with more dementia cases is needed to confirm our findings. 5 key findings →
Design: longitudinal study Participants: 1,483 Evidence: high
Full summary, score breakdown and related studies → Original source
We investigated brain, inflammation, cardiometabolic, and gut health changes associated with a six-month multidomain lifestyle intervention in Dutch older adults at risk for cognitive decline and dementia. 5 key findings →
Participants: 53 Evidence: high
Full summary, score breakdown and related studies → Original source
AD prevention must transcend the "geriatric disease" mindset. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
From 12,770 records, 3,636 duplicates were removed and 9,134 titles and abstracts were screened. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Multidomain interventions have small but consistent beneficial effects on cognitive measures, suggesting the potential to reduce cognitive impairment and dementia risk. 3 key findings →
Design: systematic review Participants: 23,209 Evidence: high
Full summary, score breakdown and related studies → Original source
Of total 8,321 participants, 24.88% (2,070) developed cognitive impairment during a 10-year follow-up. 5 key findings →
Design: longitudinal study Participants: 8,321 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Specific disease clusters involving diabetes, oral disease, sensory impairment, and osteoporosis were associated with suspected dementia and neuropsychiatric heterogeneity, supporting integrated multimorbidity-oriented screening and care. 4 key findings →
Participants: 2,597 Evidence: low
Full summary, score breakdown and related studies → Original source
Absolute BPV was associated with mortality, and DBP and MAP variability with overall stroke, after accounting for glycemic status and mean blood pressure. 5 key findings →
Design: prospective cohort Participants: 57,611 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Vascular dementia (VaD) is a leading cause of cognitive decline with no disease-modifying therapies. 2 key findings →
Participants: 437,749 Evidence: low
Full summary, score breakdown and related studies → Original source
Hypertension is associated with lower risk of dementia-related outcomes in aECAD patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Middle East and North Africa (MENA) region represents the area of greatest projected growth in instances of Alzheimer’s disease and related dementias (ADRDs) globally, yet, it remains virtually uncharacterized in health studies of aging and ADRDs. 4 key findings →
Participants: 3,552 Evidence: low
Full summary, score breakdown and related studies → Original source
The 2,885 participants had a mean age of 69.5 years. 4 key findings →
Design: longitudinal study Participants: 2,885 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Electronic health records linked documented glucosamine use to faster progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) and poorer survival after dementia. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
INTRODUCTIONLittle is understood about the extent to which lifestyle factors can advance or delay the risk of developing dementia, and whether that is dependent on non-modifiable factors, e.g. sex and genetic susceptibility.METHODSAmong 224,516 UK Biobank participants aged ≥50 years at baseline, Cox regression examined the relations of apolipoprotein E gene (APOE) genotypes, and lifestyle with incident dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
8 of the 309 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events